Effects of Standardized Extract of Ginseng (G115) on Biomarkers of Systemic Low-Grade Inflammation in Patients with Type 2 diabetes: A Double-blind Clinical Trial

Systemic Inflammation plays a crutal play in the development of cardiovascular disease in patients with Type 2 diabetes. The aim of this study was to investigate the effect of standardized extract of ginseng (G115) in Biomarkers of Systemic Low-Grade Inflammation in patients with Type 2 diabetes. This randomized, double-blind trial was performed on 40 patients with type 2 diabetes (28 females and 12 males) were randomly assigned to two groups. Group one were given 300 mg (3×100 mg capsules) standardized extract of ginseng, while group 2 took placebos. After eight weeks, anthropometric indices, glycosylated hemoglobin (HbA1c), interleukin 6 (IL6), tumor necrosis factor (TNFα) and high sensitive C- Reactive Protein (hsCRP) were studied. In the present study, no significant differences were observed in anthropometric indices, glycated hemoglobin and TNFα in the intervention and placebo groups before and after intervention. At the end of the study, a significant reduction was observed in IL6 (8.43± 1.17 vs. 6.79±1.39 ng/L) and hsCRP (3.61±0.49 vs. 3.03±0.33 mg/dL) in the treatment group. Furthermore, there was a significant difference in IL6 (6.79±1.39 vs. 7.85±0.69 ng/L) and hsCRP (3.03±0.33 vs. 3.49±0.39 mg/dL) between the intervention and placebo groups at the end of the study. Administration of standardized ginseng extract for eight weeks caused reductions in IL6 and hsCRP in patients with type 2 diabetes. Therefore, administration of standardized extract of ginseng may play an effective role in the management of these patients.